PD-L1 deletion or blockade regulate macrophage antigen presentation and checkpoint molecule surface levels.

Area of Science:

• Immunology
• Cancer Biology
• Cellular Biology

Background:

• Macrophages in the tumor microenvironment often express PD-L1, contributing to T cell suppression via PD-1.
• The intrinsic effects of PD-L1 on macrophage phenotype and function remain incompletely understood.
• Understanding these intrinsic roles is crucial for deciphering tumor immune evasion mechanisms.

Purpose of the Study:

• To investigate the intrinsic role of PD-L1 in regulating macrophage immunomodulatory functions.
• To compare the effects of genetic PD-L1 deletion versus PD-L1 blockade on macrophage phenotype.

Main Methods:

• Utilized primary murine bone marrow-derived macrophages (BMDMs) with genetic PD-L1 deletion.
• Employed anti-PD-L1 blocking antibodies on wildtype BMDMs.
• Assessed macrophages across naïve, M1 (pro-inflammatory), and TCM (tumor-conditioned) states in vitro.

Main Results:

• Neither genetic PD-L1 deletion nor antibody blockade significantly altered macrophage polarization markers or phagocytic capacity.
• Both approaches reduced surface CD80 expression on macrophages.
• Genetic deletion and antibody blockade exhibited distinct effects on surface levels of MHCI, MHCII, PD-1, and PD-L2.

Conclusions:

• PD-L1 plays a role in macrophage immune regulation independent of its canonical PD-1 ligand function.
• Genetic and pharmacological PD-L1 inhibition yield different outcomes on macrophage surface protein expression.
• These findings highlight distinct mechanisms by which PD-L1 influences the tumor microenvironment's immune landscape.